LOXL2 and neoplasm: For the first time, our data reveal that the tumor‐promoting role of LOXL2 in ESCC probably perturbs the architecture of the actin cytoskeleton through its PPIs and induces additional oncogenic effects by hyperactivation or loss‐of‐function of key proteins.